CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other disposition IA/Managing Member of 10% Owne disposed of 4,338 shares (other)
- 4/A Open-market buy IA/Managing Member of 10% owne bought 4,965 shares at an average $25.35 ($125,863)
- 4/A Open-market buy IA/Managing Member of 10% owne bought 2,800 shares at an average $26.46 ($74,100)
- 4/A Open-market buy IA/Managing Member of 10% owne bought 8,600 shares at an average $26.98 ($232,056)
- 3/A Insider 3/A
- 4 Open-market buy IA/Managing Member 10% owner bought 4,965 shares at an average $25.35 ($125,863)
- 4 Open-market buy IA/Managing Member 10% owner bought 2,800 shares at an average $26.46 ($74,100)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy IA/Managing Member 10% owner bought 8,600 shares at an average $26.98 ($232,056)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 50,000 shares at $17.00 ($850,000)
- 4 Conversion 10% owner acquired 2,679,802 shares (conversion)
- 4 Conversion 10% owner acquired 2,886,530 shares (conversion)
- 4 Conversion Director acquired 1,925,165 shares (conversion)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 10 of 11 · 211 filings